BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15134514)

  • 1. Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications.
    Andronati SA; Karaseva TL; Krysko AA
    Curr Med Chem; 2004 May; 11(9):1183-211. PubMed ID: 15134514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RGD mimetics containing phthalimidine fragment as novel ligands of fibrinogen receptor.
    Krysko AA; Samoylenko GV; Polishchuk PG; Andronati SA; Kabanova TA; Khristova TM; Kuz'min VE; Kabanov VM; Krysko OL; Varnek AA; Grygorash RY
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5971-4. PubMed ID: 21852128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp.
    Varon D; Lider O; Dardik R; Shenkman B; Alon R; Hershkoviz R; Kapustina G; Savion N; Martinowitz U; Greenspoon N
    Thromb Haemost; 1993 Dec; 70(6):1030-6. PubMed ID: 8165596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally active peptidomimetic RGD analogs that are glycoprotein IIb/IIIa antagonists.
    Wang W; Borchardt RT; Wang B
    Curr Med Chem; 2000 Apr; 7(4):437-53. PubMed ID: 10702618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold.
    Stilz HU; Guba W; Jablonka B; Just M; Klingler O; König W; Wehner V; Zoller G
    J Med Chem; 2001 Apr; 44(8):1158-76. PubMed ID: 11312916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.
    Sugihara H; Fukushi H; Miyawaki T; Imai Y; Terashita Z; Kawamura M; Fujisawa Y; Kita S
    J Med Chem; 1998 Feb; 41(4):489-502. PubMed ID: 9484499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
    Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD
    Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The integrin alpha IIb beta 3 contains distinct and interacting binding sites for snake-venom RGD (Arg-Gly-Asp) proteins. Evidence that the receptor-binding characteristics of snake-venom RGD proteins are related to the amino acid environment flanking the sequence RGD.
    Rahman S; Lu X; Kakkar VV; Authi KS
    Biochem J; 1995 Nov; 312 ( Pt 1)(Pt 1):223-32. PubMed ID: 7492316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the binding of 3H-SR121566, an inhibitor of Gp IIb-IIIa activation.
    Savi P; Zamboni G; Rescanières O; Herbert JM
    Thromb Haemost; 2001 Apr; 85(4):702-9. PubMed ID: 11341508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study.
    Anderluh M; Cesar J; Stefanic P; Kikelj D; Janes D; Murn J; Nadrah K; Tominc M; Addicks E; Giannis A; Stegnar M; Dolenc MS
    Eur J Med Chem; 2005 Jan; 40(1):25-49. PubMed ID: 15642407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antiaggregatory activity of RGD-peptidomimetics based on 4-oxo-4-(piperazine-1-yl)butyric acid as Arg-mimetic.
    Andronati SA; Krysko AA; Kabanov VM; Kabanova TA; Karaseva TL; Chugunov BM; Meshkova SB; Topilova ZM
    Acta Pol Pharm; 2003; 60(5):375-81. PubMed ID: 15005421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel fibrinogen receptor antagonists. RGDF mimetics, derivatives of 4-(isoindoline-5-yl)amino-4-oxobutyric acid.
    Krysko AA; Chugunov BM; Malovichko OL; Andronati SA; Kabanova TA; Karaseva TL; Kiriyak AV
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5533-5. PubMed ID: 15482918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Derivatives of 1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid as novel fibrinogen receptor antagonists.
    Malovichko OL; Krysko AA; Kabanova TA; Andronati SA; Grishkovets VI; Kachala VV; Panov DA
    Med Chem; 2009 Mar; 5(2):158-64. PubMed ID: 19275714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and structure--activity relationship studies of a novel and specific peptide motif, Pro-X-X-X-Asp-X, as a platelet fibrinogen receptor antagonist.
    Hayashi Y; Katada J; Sato Y; Igarashi K; Takiguchi Y; Harada T; Muramatsu M; Yasuda E; Uno I
    Bioorg Med Chem; 1998 Mar; 6(3):355-64. PubMed ID: 9568289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and properties of peptidomimetics--inhibitors of platelet aggregation.
    Andronati SA; Krysko AA; Kabanov VM; Karaseva TL; Kabanova TA
    Acta Pol Pharm; 2000 Nov; 57 Suppl():15-21. PubMed ID: 11293251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human platelet activation is inhibited by the occupancy of glycoprotein IIb/IIIa receptor.
    Padoin E; Alexandre A; Cavallini L; Polverino de Laureto P; Rao GH; Doni MG
    Arch Biochem Biophys; 1996 Sep; 333(2):407-13. PubMed ID: 8809080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agents.
    Bovy PR; Tjoeng FS; Rico JG; Rogers TE; Lindmark RJ; Zablocki JA; Garland RB; McMackins DE; Dayringer H; Tóth MV
    Bioorg Med Chem; 1994 Sep; 2(9):881-95. PubMed ID: 7712124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore refinement of gpIIb/IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides.
    Müller G; Gurrath M; Kessler H
    J Comput Aided Mol Des; 1994 Dec; 8(6):709-30. PubMed ID: 7738606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-peptide RGD surrogates which mimic a Gly-Asp beta-turn: potent antagonists of platelet glycoprotein IIb-IIIa.
    Fisher MJ; Gunn B; Harms CS; Kline AD; Mullaney JT; Nunes A; Scarborough RM; Arfsten AE; Skelton MA; Um SL; Utterback BG; Jakubowski JA
    J Med Chem; 1997 Jun; 40(13):2085-101. PubMed ID: 9207949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.